NervGen Pharma Corp.
NGEN.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.05% | -58.14% | 2.81% | -19.44% | -61.34% |
| Total Depreciation and Amortization | -8.18% | -65.85% | -60.21% | -60.81% | -57.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.49% | 54.50% | -21.54% | -101.67% | 36.66% |
| Change in Net Operating Assets | 88.84% | 90.98% | 146.06% | -921.27% | -2.66% |
| Cash from Operations | 13.30% | -19.15% | -15.25% | -295.86% | -105.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 198.36% | -- | -- | 118.28% | -- |
| Cash from Investing | 198.36% | -- | -- | 117.93% | 377.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 2,901.40% | -92.55% | 235.20% | 202.25% | -41.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -427.74% | 71.29% | -- | -- | -- |
| Cash from Financing | 4,124.97% | -94.56% | 302.73% | 266.30% | -56.98% |
| Foreign Exchange rate Adjustments | -71.73% | 119.09% | -253.09% | -146.45% | 262.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.79% | -114.09% | -16.30% | -320.86% | -89.58% |